Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based ...

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact ...

Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and ...

Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including ...

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.